Because semaglutide reduces appetite, there's a theoretical worry that mothers might not eat enough calories to maintain good milk production
Rybelsus Rybelsus, the oral tablet form of semaglutide, expires two years from the date of manufacture
Individual results may vary, and side effects may differ from person to person
Sstudies show that nausea is the most common stomach-related side effect, affecting 15-50% of people, especially in the first 4-5 weeks of treatment
The STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial programme demonstrated that adults using semaglutide 2.4 mg weekly alongside lifestyle intervention lost an average of approximately 15% of their body weight over 68 weeks, compared to around 2.4% with placebo. NICE approved Wegovy for use in specialist weight management services in the UK in 2023 (TA875), recognising its clinical effectiveness. Ongoing research continues to explore its cardiovascular benefits, with the SELECT trial showing a significant reduction in major cardiovascular events in people with obesity